These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17617025)

  • 1. Third Santorini conference pharmacogenomics workshop report: "Pharmacogenomics at the crossroads: what else than good science will be needed for the field to become part of Personalized Medicine?".
    Llerena A; Michel G; Jeannesson E; Wong S; Manolopoulos VG; Hockett RD; Boubekeur K; Siest G; Beaune P; Haefliger C; Arnold HP; Junien C; Petrovic N; Molloy R; Bekers O; Donnelly C; Arens HJ; Kaput J; McComb J
    Clin Chem Lab Med; 2007; 45(7):843-50. PubMed ID: 17617025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education.
    Gurwitz D; Lunshof JE; Dedoussis G; Flordellis CS; Fuhr U; Kirchheiner J; Licinio J; Llerena A; Manolopoulos VG; Sheffield LJ; Siest G; Torricelli F; Vasiliou V; Wong S
    Pharmacogenomics J; 2005; 5(4):221-5. PubMed ID: 15852053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating pharmacogenomics into pharmacy practice via medication therapy management.
    Reiss SM;
    J Am Pharm Assoc (2003); 2011; 51(6):e64-74. PubMed ID: 22001957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics and personalized medicine in clinical practice.
    Manolopoulos VG; Dechairo B; Huriez A; Kühn A; Llerena A; van Schaik RH; Yeo KT; Ragia G; Siest G
    Pharmacogenomics; 2011 May; 12(5):597-610. PubMed ID: 21619425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
    Little S
    IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics: bridging the gap between science and practice.
    Lee KC; Ma JD; Kuo GM
    J Am Pharm Assoc (2003); 2010; 50(1):e1-14; quiz e15-7. PubMed ID: 20368146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics: the promise of personalized medicine for CNS disorders.
    de Leon J
    Neuropsychopharmacology; 2009 Jan; 34(1):159-72. PubMed ID: 18800072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of pharmacogenomics for drug development and clinical practice.
    Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
    Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Institutional Profile: Golden Helix Institute of Biomedical Research: interdisciplinary research and educational activities in pharmacogenomics and personalized medicine.
    Mitropoulos K; Innocenti F; van Schaik RH; Lezhava A; Tzimas G; Kollia P; Macek M; Fortina P; Patrinos GP
    Pharmacogenomics; 2012 Mar; 13(4):387-92. PubMed ID: 22379996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enabling pharmacogenomic clinical trials through sampling.
    Warner A; Nelsen A; Bhathena A; Fitzgerald K; Gilardi S; Kelso E; Knoppers B; McLeod HL; Nelson R; Uyama Y; Weisman J; Rudman A
    Pharmacogenomics; 2010 Dec; 11(12):1649-54. PubMed ID: 21142907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics and its potential impact on drug and formulation development.
    Regnstrom K; Burgess DJ
    Crit Rev Ther Drug Carrier Syst; 2005; 22(5):465-92. PubMed ID: 16313234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How molecular medicine transforms policy (and everything else).
    Kean MA; Batchelder KF
    J Biolaw Bus; 2004; 7(3):16-9. PubMed ID: 15460603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Students' knowledge and views on pharmacogenomic education in the medical curriculum.
    Agrawal M; Kirtania L; Jha A; Hishikar R
    Indian J Pharmacol; 2021; 53(1):19-24. PubMed ID: 33975995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing the evidence base for applying pharmacogenomics: proceeds from DIA Workshop IV--Breakout Session 1.
    Armstrong M; Bromley C; Cohen N; Hunt CM; O'Neill R; Power A
    Pharmacogenomics; 2009 Jan; 10(1):117-25. PubMed ID: 19102721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and economic challenges facing pharmacogenomics.
    Cohen J; Wilson A; Manzolillo K
    Pharmacogenomics J; 2013 Aug; 13(4):378-88. PubMed ID: 22231566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translating pharmacogenomics: challenges on the road to the clinic.
    Swen JJ; Huizinga TW; Gelderblom H; de Vries EG; Assendelft WJ; Kirchheiner J; Guchelaar HJ
    PLoS Med; 2007 Aug; 4(8):e209. PubMed ID: 17696640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International Conference on Harmonisation; Guidance on E15 Pharmacogenomics Definitions and Sample Coding; Availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Apr; 73(68):19074-6. PubMed ID: 18677821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoliberal technocracy: explaining how and why the US Food and Drug Administration has championed pharmacogenomics.
    Hogarth S
    Soc Sci Med; 2015 Apr; 131():255-62. PubMed ID: 25661300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in pharmacogenomics and its promise for medicine.
    Blake CA; Sobel BE
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
    Goodsaid F; Frueh FW
    Environ Mol Mutagen; 2007 Jun; 48(5):354-8. PubMed ID: 17567848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.